Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

Carol VanderZwaag, Mark McGee, Joseph Patrick McEvoy, Oliver Freudenreich, William H. Wilson, Thomas B. Cooper

Research output: Contribution to journalArticle

141 Citations (Scopus)

Abstract

Objective: This study sought to determine the relationships between serum clozapine levels and therapeutic response. Method: Fifty-six inpatients who met the DSM-III-R criteria for chronic schizophrenia and who had not responded to extended treatment with classical antipsychotics were randomly assigned to 12 weeks of double-blind treatment with clozapine at one of three serum level ranges: low (50-150 ng/ml), medium (200-300 ng/ml), or high (350- 450 ng/ml). Baseline clinical assessments were completed before the patients' regular antipsychotic and anticholinergic drugs were discontinued. During clozapine treatment, serum levels were ascertained weekly to allow adjustment of clozapine doses so as to maintain each patient near the midpoint of his or her assigned serum level range. Clinical assessments were completed after 6 and 12 weeks of treatment. Results: The analyses of the results of treatment supported the superior efficacy of the 200-300 ng/ml and 350-450 ng/ml serum clozapine level ranges over the 50-150 ng/ml range, with no advantage for 350-450 ng/ml over 200-300 ng/ml. Sleepiness increased with increasing serum levels. Conclusions: Serum clozapine levels per unit of daily dose were at the lower end of the range noted in previous reports, possibly reflecting the current study's dosing schedules of twice or three times a day, the 11- to 13-hour postdose sampling time, and the moderate doses given. Serum clozapine levels, if interpreted in relation to daily clozapine dosing schedules, postdose sampling time, and total daily dose, may help to guide dosing to provide adequate opportunities for therapeutic response and to limit certain side effects of clozapine treatment.

Original languageEnglish (US)
Pages (from-to)1579-1584
Number of pages6
JournalAmerican Journal of Psychiatry
Volume153
Issue number12
DOIs
StatePublished - Jan 1 1996
Externally publishedYes

Fingerprint

Clozapine
Schizophrenia
Serum
Therapeutics
Antipsychotic Agents
Appointments and Schedules
Social Adjustment
Cholinergic Antagonists
Diagnostic and Statistical Manual of Mental Disorders
Inpatients

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. / VanderZwaag, Carol; McGee, Mark; McEvoy, Joseph Patrick; Freudenreich, Oliver; Wilson, William H.; Cooper, Thomas B.

In: American Journal of Psychiatry, Vol. 153, No. 12, 01.01.1996, p. 1579-1584.

Research output: Contribution to journalArticle

VanderZwaag, Carol ; McGee, Mark ; McEvoy, Joseph Patrick ; Freudenreich, Oliver ; Wilson, William H. ; Cooper, Thomas B. / Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges. In: American Journal of Psychiatry. 1996 ; Vol. 153, No. 12. pp. 1579-1584.
@article{e25698ebf1df43539114ef8a5020857d,
title = "Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges",
abstract = "Objective: This study sought to determine the relationships between serum clozapine levels and therapeutic response. Method: Fifty-six inpatients who met the DSM-III-R criteria for chronic schizophrenia and who had not responded to extended treatment with classical antipsychotics were randomly assigned to 12 weeks of double-blind treatment with clozapine at one of three serum level ranges: low (50-150 ng/ml), medium (200-300 ng/ml), or high (350- 450 ng/ml). Baseline clinical assessments were completed before the patients' regular antipsychotic and anticholinergic drugs were discontinued. During clozapine treatment, serum levels were ascertained weekly to allow adjustment of clozapine doses so as to maintain each patient near the midpoint of his or her assigned serum level range. Clinical assessments were completed after 6 and 12 weeks of treatment. Results: The analyses of the results of treatment supported the superior efficacy of the 200-300 ng/ml and 350-450 ng/ml serum clozapine level ranges over the 50-150 ng/ml range, with no advantage for 350-450 ng/ml over 200-300 ng/ml. Sleepiness increased with increasing serum levels. Conclusions: Serum clozapine levels per unit of daily dose were at the lower end of the range noted in previous reports, possibly reflecting the current study's dosing schedules of twice or three times a day, the 11- to 13-hour postdose sampling time, and the moderate doses given. Serum clozapine levels, if interpreted in relation to daily clozapine dosing schedules, postdose sampling time, and total daily dose, may help to guide dosing to provide adequate opportunities for therapeutic response and to limit certain side effects of clozapine treatment.",
author = "Carol VanderZwaag and Mark McGee and McEvoy, {Joseph Patrick} and Oliver Freudenreich and Wilson, {William H.} and Cooper, {Thomas B.}",
year = "1996",
month = "1",
day = "1",
doi = "10.1176/ajp.153.12.1579",
language = "English (US)",
volume = "153",
pages = "1579--1584",
journal = "American Journal of Psychiatry",
issn = "0002-953X",
publisher = "American Psychiatric Association",
number = "12",

}

TY - JOUR

T1 - Response of patients with treatment-refractory schizophrenia to clozapine within three serum level ranges

AU - VanderZwaag, Carol

AU - McGee, Mark

AU - McEvoy, Joseph Patrick

AU - Freudenreich, Oliver

AU - Wilson, William H.

AU - Cooper, Thomas B.

PY - 1996/1/1

Y1 - 1996/1/1

N2 - Objective: This study sought to determine the relationships between serum clozapine levels and therapeutic response. Method: Fifty-six inpatients who met the DSM-III-R criteria for chronic schizophrenia and who had not responded to extended treatment with classical antipsychotics were randomly assigned to 12 weeks of double-blind treatment with clozapine at one of three serum level ranges: low (50-150 ng/ml), medium (200-300 ng/ml), or high (350- 450 ng/ml). Baseline clinical assessments were completed before the patients' regular antipsychotic and anticholinergic drugs were discontinued. During clozapine treatment, serum levels were ascertained weekly to allow adjustment of clozapine doses so as to maintain each patient near the midpoint of his or her assigned serum level range. Clinical assessments were completed after 6 and 12 weeks of treatment. Results: The analyses of the results of treatment supported the superior efficacy of the 200-300 ng/ml and 350-450 ng/ml serum clozapine level ranges over the 50-150 ng/ml range, with no advantage for 350-450 ng/ml over 200-300 ng/ml. Sleepiness increased with increasing serum levels. Conclusions: Serum clozapine levels per unit of daily dose were at the lower end of the range noted in previous reports, possibly reflecting the current study's dosing schedules of twice or three times a day, the 11- to 13-hour postdose sampling time, and the moderate doses given. Serum clozapine levels, if interpreted in relation to daily clozapine dosing schedules, postdose sampling time, and total daily dose, may help to guide dosing to provide adequate opportunities for therapeutic response and to limit certain side effects of clozapine treatment.

AB - Objective: This study sought to determine the relationships between serum clozapine levels and therapeutic response. Method: Fifty-six inpatients who met the DSM-III-R criteria for chronic schizophrenia and who had not responded to extended treatment with classical antipsychotics were randomly assigned to 12 weeks of double-blind treatment with clozapine at one of three serum level ranges: low (50-150 ng/ml), medium (200-300 ng/ml), or high (350- 450 ng/ml). Baseline clinical assessments were completed before the patients' regular antipsychotic and anticholinergic drugs were discontinued. During clozapine treatment, serum levels were ascertained weekly to allow adjustment of clozapine doses so as to maintain each patient near the midpoint of his or her assigned serum level range. Clinical assessments were completed after 6 and 12 weeks of treatment. Results: The analyses of the results of treatment supported the superior efficacy of the 200-300 ng/ml and 350-450 ng/ml serum clozapine level ranges over the 50-150 ng/ml range, with no advantage for 350-450 ng/ml over 200-300 ng/ml. Sleepiness increased with increasing serum levels. Conclusions: Serum clozapine levels per unit of daily dose were at the lower end of the range noted in previous reports, possibly reflecting the current study's dosing schedules of twice or three times a day, the 11- to 13-hour postdose sampling time, and the moderate doses given. Serum clozapine levels, if interpreted in relation to daily clozapine dosing schedules, postdose sampling time, and total daily dose, may help to guide dosing to provide adequate opportunities for therapeutic response and to limit certain side effects of clozapine treatment.

UR - http://www.scopus.com/inward/record.url?scp=0029903903&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029903903&partnerID=8YFLogxK

U2 - 10.1176/ajp.153.12.1579

DO - 10.1176/ajp.153.12.1579

M3 - Article

VL - 153

SP - 1579

EP - 1584

JO - American Journal of Psychiatry

JF - American Journal of Psychiatry

SN - 0002-953X

IS - 12

ER -